Current Gastroenterology Reports最新文献_第5页

Artificial Intelligence Tools for Improving Manometric Diagnosis of Esophageal Dysmotility. 改进食道运动障碍人工计量诊断的人工智能工具。

Current Gastroenterology Reports Pub Date : 2024-04-01 Epub Date: 2024-02-07 DOI: 10.1007/s11894-024-00921-z

Ofer Fass, Benjamin D Rogers, C Prakash Gyawali

{"title":"Artificial Intelligence Tools for Improving Manometric Diagnosis of Esophageal Dysmotility.","authors":"Ofer Fass, Benjamin D Rogers, C Prakash Gyawali","doi":"10.1007/s11894-024-00921-z","DOIUrl":"10.1007/s11894-024-00921-z","url":null,"abstract":"Purpose of review: Artificial intelligence (AI) is a broad term that pertains to a computer's ability to mimic and sometimes surpass human intelligence in interpretation of large datasets. The adoption of AI in gastrointestinal motility has been slower compared to other areas such as polyp detection and interpretation of histopathology.Recent findings: Within esophageal physiologic testing, AI can automate interpretation of image-based tests, especially high resolution manometry (HRM) and functional luminal imaging probe (FLIP) studies. Basic tasks such as identification of landmarks, determining adequacy of the HRM study and identification from achalasia from non-achalasia patterns are achieved with good accuracy. However, existing AI systems compare AI interpretation to expert analysis rather than to clinical outcome from management based on AI diagnosis. The use of AI methods is much less advanced within the field of ambulatory reflux monitoring, where challenges exist in assimilation of data from multiple impedance and pH channels. There remains potential for replication of the AI successes within esophageal physiologic testing to HRM of the anorectum, and to innovative and novel methods of evaluating gastric electrical activity and motor function. The use of AI has tremendous potential to improve detection of dysmotility within the esophagus using esophageal physiologic testing, as well as in other regions of the gastrointestinal tract. Eventually, integration of patient presentation, demographics and alternate test results to individual motility test interpretation will improve diagnostic precision and prognostication using AI tools.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"115-123"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10960670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139697052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

H. Pylori Treatment in the COVID-19 Era. What Have We Learned So Far? H.COVID-19 时代的幽门螺杆菌治疗。我们目前学到了什么？

Current Gastroenterology Reports Pub Date : 2024-03-01 Epub Date: 2024-02-02 DOI: 10.1007/s11894-024-00922-y

Konstantinos Ekmektzoglou, Theodore Rokkas

{"title":"H. Pylori Treatment in the COVID-19 Era. What Have We Learned So Far?","authors":"Konstantinos Ekmektzoglou, Theodore Rokkas","doi":"10.1007/s11894-024-00922-y","DOIUrl":"10.1007/s11894-024-00922-y","url":null,"abstract":"Purpose of review: CoronaVirus Disease of 2019 (COVID-19) has negatively influenced the management of multiple conditions in regards to the gastroenterology patient. An equivalent change in the management of Helicobacter pylori (H. pylori)-related diseases was reported, as practically no eradication treatment was offered during most of the pandemic. Given the scarcity of published data, we performed a literature review trying to elucidate the effect of COVID-19 on H. pylori treatment.Recent findings: COVID-19 has produced more questions than answers as to the outcome of COVID-19 in H. Pylori infected patients, post-COVID-19 patients treated for H. pylori, acid suppression and COVID-19 incidence and outcomes, and H. pylori eradication treatment in patients having recovered from COVID-19. We strongly believe that this scientific uncertainty produced by the COVID-19 pandemic has set up the stage for an incremental change in H. pylori treatment as COVID-19 has offered us the chance to speed up how we will, in the near future, approach patients with a possible Η. pylori infection.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"86-91"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Gastroenterology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-20 DOI: 10.1007/s11894-023-00913-5

Anthony Angyal, Shubha Bhat

引用次数: 0

Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies. 在晚期胃食管恶性肿瘤中单独或与免疫检查点抑制剂联合靶向血管生成

Current Gastroenterology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1007/s11894-024-00920-0

Alireza Tojjari, Robin Park, James Yu, Anwaar Saeed

{"title":"Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies.","authors":"Alireza Tojjari, Robin Park, James Yu, Anwaar Saeed","doi":"10.1007/s11894-024-00920-0","DOIUrl":"10.1007/s11894-024-00920-0","url":null,"abstract":"Purpose of review: This review critically examines the latest approaches in treating advanced gastroesophageal malignancies. It emphasizes the significance of angiogenesis as a therapeutic target and discusses the potential synergy of combining angiogenesis inhibitors with immune checkpoint inhibitors (ICIs) to enhance treatment efficacy.Recent findings: Emerging evidence from clinical trials, such as the INTEGRATE IIa trial with regorafenib and studies involving apatinib and sunitinib, underscores the efficacy of targeting the VEGFR pathway. These studies indicate substantial benefits in progression-free survival (PFS) and overall survival (OS) in patients with advanced stages of the disease who have limited treatment options. Additionally, the recent introduction of combination therapies involving ICIs has shown an increased response rate, suggesting a promising direction for future treatment protocols. The landscape of treatment for gastroesophageal malignancies is rapidly evolving. Research is now pivoting from conventional chemotherapy to a more nuanced approach that includes targeted therapy and immunotherapy.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"57-67"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Therapies for Inflammatory Bowel Disease: Navigating Payor and Financial Challenges. 炎症性肠病的先进疗法：应对支付方和财务挑战。

Current Gastroenterology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-20 DOI: 10.1007/s11894-024-00916-w

Natalie Whitmire, Michelle Schlueter, Melissa Kirkpatrick

引用次数: 0

Clinical Update on the Prevention and Management of Postoperative Crohn's Disease Recurrence. 预防和处理克罗恩病术后复发的临床最新进展。

Current Gastroenterology Reports Pub Date : 2024-02-01 Epub Date: 2024-01-16 DOI: 10.1007/s11894-023-00911-7

Salam P Bachour, Benjamin H Click

{"title":"Clinical Update on the Prevention and Management of Postoperative Crohn's Disease Recurrence.","authors":"Salam P Bachour, Benjamin H Click","doi":"10.1007/s11894-023-00911-7","DOIUrl":"10.1007/s11894-023-00911-7","url":null,"abstract":"Purpose of review: Despite advances in therapeutics, a significant portion of patients with Crohn's disease still require surgical management. In this article, we present updates to the natural history, prognostication and postoperative monitoring, and novel therapeutics in the prevention and treatment of postoperative Crohn's disease recurrence.Recent findings: Clinical risk factors have been associated with higher rates of postoperative recurrence (POR), and in recent studies demonstrate an increased cumulative risk with presence of additional risk factors. Additional novel clinical, histologic, and \"-omic\" risk factors for recurrence have recently been elucidated, including the role of the mesentery on recurrence and perioperative intraabdominal septic complications. High-risk patients benefit most from medical prophylaxis, including anti-TNF with or without immunomodulator therapy to prevent recurrence. New biologics such as vedolizumab and ustekinumab have emerging evidence in the use of prophylaxis, especially with recent REPREVIO trial data. Non-invasive disease monitoring, such as cross-sectional enterography, intestinal ultrasound, and fecal calprotectin, have been validated against ileocolonoscopy. Recent advances in the prediction, prevention, and monitoring algorithms of postoperative Crohn's disease may be leading to a reduction in postoperative recurrence. Ongoing trials will help determine optimal monitoring and management strategies for this at-risk population.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"41-52"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistent Ostomy Following Percutaneous Endoscopic Gastrostomy Removal: Treatment Strategies. 经皮内镜胃造口术后持续造口：治疗策略。

Current Gastroenterology Reports Pub Date : 2024-02-01 Epub Date: 2024-01-09 DOI: 10.1007/s11894-023-00912-6

Alsiddig Elmahdi, Mohamed Eisa, Robert Martindale, Endashaw Omer

{"title":"Persistent Ostomy Following Percutaneous Endoscopic Gastrostomy Removal: Treatment Strategies.","authors":"Alsiddig Elmahdi, Mohamed Eisa, Robert Martindale, Endashaw Omer","doi":"10.1007/s11894-023-00912-6","DOIUrl":"10.1007/s11894-023-00912-6","url":null,"abstract":"Purpose of review: The purpose of this article is to review available literature on management of persistent ostomy following PEG tube removal. We will discuss the incidence of persistent gastrocutaneous fistula (GCF) following PEG tube removal, risk factors for their development, and management strategies that have been proposed and their efficacy.Recent findings: The use of over the scope clips (OTSC) have evolved recently in the management of gastrointestinal bleeding, perforation, and fistula closures. OTSC has become more readily available and proven to be effective and safe. Suturing devices have shown promising results. Persistent gastrocutaneous fistula following PEG removal is a rare yet serious complication that can lead to continuous skin irritation and leakage of gastric contents and acid. There are several postulated risk factors but the most important of these is duration of placement. Management can include medical therapy which has recently been shown to be somewhat effective, endoscopic therapy and surgery as a last resort. Overall, the data on GCFs is limited and further study with larger sample size is needed.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"53-56"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease. 肠道超声在炎症性肠病中的临床应用。

Current Gastroenterology Reports Pub Date : 2024-02-01 Epub Date: 2024-01-20 DOI: 10.1007/s11894-024-00915-x

Noa Krugliak Cleveland, Joëlle St-Pierre, Amelia Kellar, David T Rubin

{"title":"Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease.","authors":"Noa Krugliak Cleveland, Joëlle St-Pierre, Amelia Kellar, David T Rubin","doi":"10.1007/s11894-024-00915-x","DOIUrl":"10.1007/s11894-024-00915-x","url":null,"abstract":"Purpose of review: Intestinal ultrasound (IUS) is a non-invasive, accurate, and well-tolerated tool that provides real-time assessment of inflammatory bowel disease (IBD) activity and is therefore an ideal monitoring tool. This review describes the evolving role of IUS in each phase of clinical management of IBD.Recent findings: Accumulating evidence has demonstrated that IUS is an excellent tool for the assessment of suspected IBD, with a very high negative predictive value. It accurately assesses disease activity, disease complications, and in the pre-treatment phase, provides a benchmark for subsequent follow-up. IUS can detect early therapeutic response and correlates well with other established monitoring modalities with arguably superior predictive capabilities and ability to assess a deeper degree of remission, transmural healing (TH). IUS has a crucial role in the management of IBD and has ushered in a new era of monitoring with more rapid evaluation and the opportunity for early optimization, deeper therapeutic targets, and improved outcomes.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"31-40"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139502364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Getting the BS out of Irritable Bowel Syndrome with Diarrhea (IBS-D): Let's Make a Diagnosis. 摆脱肠易激综合征伴腹泻 (IBS-D) 的困扰：让我们来做个诊断。

Current Gastroenterology Reports Pub Date : 2024-01-01 Epub Date: 2023-12-30 DOI: 10.1007/s11894-023-00909-1

Christine L Frissora, Lawrence R Schiller

引用次数: 0

Managing IBD Patients with Concomitant HIV Infection - a Systematic Review. 管理合并 HIV 感染的 IBD 患者 - 系统综述。

Current Gastroenterology Reports Pub Date : 2024-01-01 Epub Date: 2024-01-05 DOI: 10.1007/s11894-023-00914-4

Hugo Sousa, Joana Barroso, Raquel Tavares, Joana Torres

{"title":"Managing IBD Patients with Concomitant HIV Infection - a Systematic Review.","authors":"Hugo Sousa, Joana Barroso, Raquel Tavares, Joana Torres","doi":"10.1007/s11894-023-00914-4","DOIUrl":"10.1007/s11894-023-00914-4","url":null,"abstract":"Purpose of review: Inflammatory Bowel Disease (IBD) is a chronic GI inflammatory condition induced by a dysregulated immune system activation, whereas HIV infection causes depletion of the immune system, inducing immunosuppression. Given the increasing incidence of IBD across the globe, including in developing countries, the co-prevalence of both conditions is expected to increase. Herein, we systematically review the data describing disease course when both pathologies co-exist.Recent findings: Overall, the co-prevalence of IBD and HIV is around 0.1 to 2%. While IBD does not seem to affect HIV course, the opposite is controversial, as some studies report milder IBD phenotype, with fewer disease relapses especially when CD4 + counts are lower than 200 cells/µL. Despite growing evidence to support the safety of the use of immunosuppressants and biologics in IBD-HIV infected patients, these classes of drugs are used in less than 50% of patients, as compared to non-HIV infected IBD patients. There is a need for more studies on disease course and safety of IBD medications in the setting of IBD.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0